THE CHALLENGE IN THE MARKET
Complexities in the market have made it increasingly challenging for pharma companies to realise the full sales potential of their pipeline assets
The market is getting more and more complex because of the growth in the amount of information:
IMPACTS TO LIFE SCIENCE COMPANIES
Increasing R&D Spend
The cost of bringing a new pharma asset to market has increased by 67% and risen in Average cost to $2BN with pharma companies looking to leverage AI for cost savings
Falling peak sales
36% of new launched fail to meet market expectations, with peak sales falling from $816M to $355M, highlighting a need to innovate commercialisation strategy
OKRA.AI IS THE BEST AI PARTNER FOR YOU
We are a proven AI platform with a rich data lake
Cutting-edge AI algorithms allow pharma companies to predict and identify opportunities and threats to the business. Transformative application of a curated data lake from data sourced across public domain, third-party providers and client systems
We have established, high-profile clients
Growing client base, now including 6 of the top 20 pharma companies
Successful track record in scaling products internationally
We validate our products with pharmaceutical clients
OKRA.ai’s AI brains have a demonstrated prediction accuracy of up to 95% against real-world scenarios for pharma clients. Products have been co-developed with pharma, allowing OKRA.ai to address real-world challenges, evidenced by client successes
We have the top talents of Artificial Intelligence
Led by a team of industry experts in pharma AI, who have been actively involved in EU AI policy development
Team of talented data scientists and engineers with 90% of these individuals in possession of a relevant advanced qualification
OKRA.ai HAS UNIQUE POSITION IN PHARMA VALUE-CHAIN
OKRA.ai has a unique positioning in the pharma value chain because we directly target the most lucrative stage of value creation.
You need OKRA.ai, because;
- The cost of bringing a new pharma asset to market has increased by 67% and risen in average cost to $2BN with pharma companies looking to leverage AI for cost savings.
- 36% of new launches fail to meet market expectations, with peak sales falling from $816M to $355M, highlighting a need to innovate a commercialisation strategy.
OKRA is at the forefront of this revolution. We offer a ‘full-platform’ solution, not a ‘point’ solution. Our product applies to every stage of this segment of value creation and all applications aim to ensure and enhance the successful launch of a new drug.
We provide value for clinical trials, launch and growth of any product launch for pharmaceutical companies.
- During Market Access: we optimise launch success by predicting new drug prices years ahead of regulatory review.
- For Medical Affairs: we optimise time to launch and drug positioning by analysing hundreds of thousands of medical notes and producing sentiment analysis. As well as guiding the scientific teams to the right Key opinion leaders in the industry.
- And for the Commercial teams: we empower sales reps with actionable insights, which HCPs they need to prioritise and what needs to be communicated all derived based on 12-month leading sales forecasts for pharma’s own brand as well as competitor’s brands
OKRA is uniquely positioned to tackle the midstream, which is the most lucrative stage of value creation. Pharma spends billions of dollars on traditional SaaS, research and consultants. Yet, this manual, dreary process is challenged by data overload today and cannot deliver quick, positive, and consistent results.
